Sanofi SA (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 232   

Articles published

SNY 54.70 0.00 (0.00%)
price chart
Pfizer Takes Lead Over Sanofi With Fast-Track Designation Of Its C. Difficile ...
The designation puts Pfizer ahead of Sanofi SA (ADR) (SNY), which is also developing a similar vaccine. While most forms of the disease can be cured with antibiotics, there currently exists no preventive care for this infection.
Related articles »  
Amgen And Sanofi Compete To Launch New Class Of Cholesterol-Fighting Drugs
... the approval of the new generation PCSK9 inhibitors. Amgen also announced positive phase 3 trial results for its drug yesterday.
Related articles »  
Sanofi, Regeneron Take Lead In Cholestrol Drug Race
Sanofi SA (ADR) (SNY) and Regeneron Pharmaceuticals Inc (REGN) are head-to-head with Amgen, Inc. (AMGN) to introduce the world's first PCSK9 inhibitor in the market.
FDA Approves Sanofi's Breakthrough Gaucher Disease Drug
Sanofi's new drug will be a breakthrough, changing the way the disease is treated. Cerdelga, also known as eliglustat, is the first oral treatment, and is designed as a pill.
Related articles »  
Sanofi SA (ADR) (NYSE:SNY) Gets Clearance From The Competition ...
Sanofi SA (ADR) (NYSE:SNY) would acquire 20% stake in Apollo Sugar Clinics Ltd (ASCL) under this deal. Other than the 20% stake, SNY will also get certain management rights in ASCL, which is a subsidiary company of Apollo Health and Lifestyle.
Sanofi Raises Guidance After Second-Quarter Profit Jump
Sanofi SA (ADR) (SNY) beat the Street's earnings expectations for the second quarter of its fiscal year '14 (2QFY14, ended June 30); the company then raised its full-year guidance.
Related articles »  
Sanofi SA (ADR) (NYSE:SNY), MannKind (NASDAQ:MNKD) In Afrezza ...
Boston, MA 08/11/2014 (wallstreetpr) - French drug company Sanofi SA (ADR) (NYSE:SNY) and MannKind Corporation (NASDAQ:MNKD) have entered a global collaboration that involves developing and marketing of the inhaled insulin therapy, Afrezza, ...
FDA Approves Genzyme's Lumizyme For All Ages
Genzyme, a subsidiary of Sanofi SA (ADR) (SNY), announced last Friday, the US Food & Drug Administration's (FDA) approval of Lumizyme (Alglucosidase Alfa) for treating all patients suffering from infantile-onset Pompe disease, including those under the ...
Related articles »  
Investor's Alert �MGIC Investment Corp. (NYSE:MTG), Sanofi SA (ADR) (NYSE ...
Birmingham, West Midlands - (TechSonian) - 08/29/2014 - Elitestockpicks.comis a Stock newsletter website that provides free daily alerts on hot Moving stocks.
Related articles »  
Best Pharma Stocks Not In The U.S. [GlaxoSmithKline plc (ADR), AbbVie Inc ...
healthcare1 Marshall Hargrave: With tax inversions being one of the hottest topics in the merger and acquisition market these days, pharma stocks are in full focus.